Skip to main content

Search

Show all results for

Home

Person

Laura Jeanbart

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (10)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity

Jeffrey Alan Hubbell, Xavier Fredy René Quaglia-Thermes, Melody Swartz, Giacomo Olimpio Diaceri, Sachiko Hirosue, Laura Jeanbart, David Scott Wilson, Maria Anna Sofia Broggi, Michal Mateusz Raczy, Ruyi Wang

Fully effective vaccines for complex infections must elicit a diverse repertoire of antibodies (humoral immunity) and CD8+ T-cell responses (cellular immunity). Here, we present a synthetic glyco-adjuvant named p(Man-TLR7), which, when conjugated to antige ...

NATURE PUBLISHING GROUP2019

Engineering opportunities in cancer immunotherapy

Melody Swartz, Laura Jeanbart

Immunotherapy has great potential to treat cancer and prevent future relapse by activating the immune system to recognize and kill cancer cells. A variety of strategies are continuing to evolve in the laboratory and in the clinic, including therapeutic non ...

National Academy of Sciences2015

Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma

Melody Swartz, Douglas Hanahan, Olivier Michielin, Krisztian Homicsko, Marcela Rincón-Restrepo, Christopher Claude Giuseppe Tremblay, Amanda Waite Lund, Laura Jeanbart, Lambert Charles François Potin, Manuel Andreas Fankhauser

In melanoma, vascular endothelial growth factor-C (VEGF-C) expression and consequent lymphangiogenesis correlate with metastasis and poor prognosis. VEGF-C also promotes tumor immunosuppression, suggesting that lymphangiogenesis inhibitors may be clinicall ...

Amer Assoc Advancement Science2017